TY - JOUR
T1 - Exploring the use and impact of adjuvant Trastuzumab for HER2-positive breast cancer patients in a large UK cancer networkDo the results of international clinical trials translate into a similar benefit for patients in South East Wales
AU - Webster, R. M.
AU - Abraham, J.
AU - Palaniappan, N.
AU - Caley, A.
AU - Jasani, B.
AU - Barrett-Lee, P.
PY - 2012/1/3
Y1 - 2012/1/3
N2 - Background: Trastuzumab was approved in the United Kingdom for adjuvant treatment of human epidermal growth factor receptor 2 (HER2) breast cancer in 2006 at significant economic cost and with limited evidence in smaller T1N0 tumours. The South East Wales Cancer Network covers a population of 1 420 000 and maintains a database of treatments used. We examined this database to ensure the outcome of Trastuzumab use is as expected, especially in patients with T1N0 cancers.Ethods:M Case notes of patients with HER2 disease eligible for adjuvant Trastuzumab over 2005-2008 were reviewed. Disease-free survival (DFS) and overall survival (OS) were calculated with the Kaplan-Meier method using SPSS (version 16.0.01 for Windows, SPSS, Chicago, IL, USA). Results: A total of 239 of 338 (70.7%) eligible HER2 patients received treatment. At 3 years, the DFS of the treated group was 90.3% vs 73.3% and the OS was 98.5% vs 87.6%. In all, 47 of 92 stage I patients received Trastuzumab. Despite a trend towards worse prognostic factors in the treated group the DFS was 100% vs 84.1% and the OS was 100% vs 93.3%. Conclusion: Our results are comparable to those from landmark Trastuzumab trials. As evidence continues to emerge that smaller HER2 cancers may behave aggressively our analysis of stage I tumours adds further support to the use of Trastuzumab in these patients.
AB - Background: Trastuzumab was approved in the United Kingdom for adjuvant treatment of human epidermal growth factor receptor 2 (HER2) breast cancer in 2006 at significant economic cost and with limited evidence in smaller T1N0 tumours. The South East Wales Cancer Network covers a population of 1 420 000 and maintains a database of treatments used. We examined this database to ensure the outcome of Trastuzumab use is as expected, especially in patients with T1N0 cancers.Ethods:M Case notes of patients with HER2 disease eligible for adjuvant Trastuzumab over 2005-2008 were reviewed. Disease-free survival (DFS) and overall survival (OS) were calculated with the Kaplan-Meier method using SPSS (version 16.0.01 for Windows, SPSS, Chicago, IL, USA). Results: A total of 239 of 338 (70.7%) eligible HER2 patients received treatment. At 3 years, the DFS of the treated group was 90.3% vs 73.3% and the OS was 98.5% vs 87.6%. In all, 47 of 92 stage I patients received Trastuzumab. Despite a trend towards worse prognostic factors in the treated group the DFS was 100% vs 84.1% and the OS was 100% vs 93.3%. Conclusion: Our results are comparable to those from landmark Trastuzumab trials. As evidence continues to emerge that smaller HER2 cancers may behave aggressively our analysis of stage I tumours adds further support to the use of Trastuzumab in these patients.
KW - HER2+
KW - adjuvant
KW - trastuzumab
UR - http://www.scopus.com/inward/record.url?scp=84855342713&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855342713&partnerID=8YFLogxK
U2 - 10.1038/bjc.2011.506
DO - 10.1038/bjc.2011.506
M3 - Article
C2 - 22108523
AN - SCOPUS:84855342713
VL - 106
SP - 32
EP - 38
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 1
ER -